$13.40
0.433.32%
Last update: Nov 9, 9:19 AM
Kailera Therapeutics Inc
KLRANASDAQ
The average analyst price target for Kailera Therapeutics is $39.50, 194.8% above the current price. Of 5 analysts, 5 rate it Buy. Targets range from $30 to $48. The latest change came on Nov 9, 2026, when Canaccord Genuity initiated coverage of Kailera Therapeutics with a Buy rating and a $44 price target.
Price Target Range — 2 Quarters
Analyst Consensus — 5 Analysts
Rating Trend — Last 9 Months
